Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce heart attacks and ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

Valentine’s Day has come and gone, but it’s never too late to focus on your heart health.  A groundbreaking new study ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...